查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1386934

全球靜脈注射免疫球蛋白市場：趨勢、預測與競爭分析（-2030）

Intravenous Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

靜脈注射免疫球蛋白的趨勢和預測

預計2030年，全球靜脈注射注射免疫球蛋白市場規模將達到約246億美元，2024年至2030年年複合成長率為7.6%。這個市場的主要驅動力是老年人口的增加、血友病患者數量的增加、免疫球蛋白生產的新技術以及精製方法的改進（提高血漿產量）。全球靜脈注射免疫球蛋白市場的未來充滿希望，醫院、居家醫療和專科診所市場充滿機會。

靜脈注射免疫球蛋白市場洞察

Lucintel 預測，由於人們越來越關注基於個別患者的診斷和治療，以及大多數患者無法適應自我給藥，因此免疫力缺乏疾病將變得更加普遍。在預測期內，免疫缺陷疾病將繼續成為最大的細分市場。

醫院將繼續成為該市場的最大細分市場。這是因為原發性免疫力缺乏症、C型肝炎等疾病的盛行率不斷上升，導致住院患者人數迅速增加，全球醫院藥局的需求也隨之增加。

由於臨床醫生對治療的需求不斷增加、醫療保健支出不斷增加以及大公司的存在，北美將繼續成為最大的地區。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個細分市場將以更快的速度成長？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和業務風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球靜脈注射免疫球蛋白市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢與預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球靜脈注射免疫球蛋白市場趨勢（2018-2023）與預測（2024-2030）
  • 全球靜脈注射免疫球蛋白市場：依應用分類
    • Hypogammaglobulinemia
    • CIPD
    • Immunodeficiency Diseases
    • Congenital AIDS
    • Chronic Lymphocytic Leukemia
    • Myasthenia Gravis
    • Multifocal Motor Neuropathy
    • Kawasaki Disease
    • Guillain-Barre Syndrome
  • 全球靜脈注射免疫球蛋白市場：依配銷通路
    • 靜脈
    • 皮下的
  • 全球靜脈注射免疫球蛋白市場：依最終用途分類
    • 醫院
    • 居家醫療
    • 專科診所
    • 其他
  • 全球靜脈注射免疫球蛋白市場：依型態
    • 液體
    • 冷凍乾燥

第4章 市場趨勢與預測分析：按地區（2018-2030）

  • 全球靜脈注射免疫球蛋白市場：按地區
  • 北美靜脈注射免疫球蛋白市場
  • 歐洲靜脈注射免疫球蛋白市場
  • 亞太靜脈靜脈注射免疫球蛋白市場
  • 其他地區靜脈注射免疫球蛋白市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球靜脈注射免疫球蛋白市場成長機會（按應用）
    • 按配銷通路的全球靜脈注射免疫球蛋白市場成長機會
    • 按最終用途分類的全球靜脈注射免疫球蛋白市場成長機會
    • 全球靜脈注射免疫球蛋白市場成長機會（按型態）
    • 全球靜脈注射免疫球蛋白市場成長機會（按地區）
  • 全球靜脈注射免疫球蛋白市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球靜脈注射免疫球蛋白市場的產能
    • 全球靜脈注射免疫球蛋白市場的合併、收購和合資企業
    • 認證和許可

第7章 主要企業概況

  • Baxter
  • Bayer
  • Merck
  • Biotest
  • Top Bio
  • CSL
  • Octapharma
  • Grifols
  • Kedrion
  • Takeda Pharmaceuical
簡介目錄

Intravenous Immunoglobulin Trends and Forecast

The future of the global intravenous immunoglobulin market looks promising with opportunities in the hospital, homecare, and specialty clinic markets. The global intravenous immunoglobulin market is expected to reach an estimated $24.6 billion by 2030 with a CAGR of 7.6% from 2024 to 2030. The major drivers for this market are increasing geriatric population, rising number of hemophiliacs, and new technologies related to the generation of immunoglobulin, and improved purification methods (with improved plasma yield).

A more than 150-page report is developed to help in your business decisions.

Intravenous Immunoglobulin by Segment

The study includes a forecast for the global intravenous immunoglobulin by application, distribution channel, end use, form, and region.

Intravenous Immunoglobulin Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Hypogammaglobulinemia
  • CIPD
  • Immunodeficiency Diseases
  • Congenital AIDs
  • Chronic Lymphocytic Leukemia
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy
  • Kawasaki Disease
  • Guillain-Barre Syndrome
  • Others

Intravenous Immunoglobulin Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Intravenous
  • Subcutaneous

Intravenous Immunoglobulin Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Intravenous Immunoglobulin Market by Form [Shipment Analysis by Value from 2018 to 2030]:

  • Liquid
  • Lyophilized

Intravenous Immunoglobulin Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Intravenous Immunoglobulin Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies intravenous immunoglobulin companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the intravenous immunoglobulin companies profiled in this report include-

  • Baxter
  • Bayer
  • Merck
  • Biotest
  • Top Bio
  • CSL
  • Octapharma
  • Grifols
  • Kedrion
  • Takeda Pharmaceuical

Intravenous Immunoglobulin Market Insights

Lucintel forecasts that immunodeficiency diseases will remain the largest segment over the forecast period due to increasing focus towards the diagnosis and treatment based on individual patient and training of patients as most of the patients are not adaptable towards self administration.

Within this market, hospital will remain the largest segment due to the increasing prevalence of primary immunodeficiency and hepatitis c, as well as other diseases, has led to surge in hospitalizations around the world, thus increasing the demand for hospital pharmacies.

North America will remain the largest region due to growing demand of therapies among clinicians, rising healthcare expenditure, and presence of major players in the region.

Features of the Global Intravenous Immunoglobulin Market

Market Size Estimates: Intravenous immunoglobulin market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Intravenous immunoglobulin market size by various segments, such as by application, distribution channel, end use, form, and region in terms of value ($B).

Regional Analysis: Intravenous immunoglobulin market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different applications, distribution channels, end uses, forms, and regions for the intravenous immunoglobulin market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the intravenous immunoglobulin market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the intravenous immunoglobulin market size?

Answer: The global intravenous immunoglobulin market is expected to reach an estimated $24.6 billion by 2030.

Q.2 What is the growth forecast for intravenous immunoglobulin market?

Answer: The global intravenous immunoglobulin market is expected to grow with a CAGR of 7.6% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the intravenous immunoglobulin market?

Answer: The major drivers for this market are increasing geriatric population, rising number of hemophiliacs, and new technologies related to the generation of immunoglobulin, and improved purification methods (with improved plasma yield).

Q4. What are the major segments for intravenous immunoglobulin market?

Answer: The future of the global intravenous immunoglobulin market looks promising with opportunities in the hospital, homecare, and specialty clinic markets.

Q5. Who are the key intravenous immunoglobulin market companies?

Answer: Some of the key intravenous immunoglobulin companies are as follows:

  • Baxter
  • Bayer
  • Merck
  • Biotest
  • Top Bio
  • CSL
  • Octapharma
  • Grifols
  • Kedrion
  • Takeda Pharmaceuical

Q6. Which intravenous immunoglobulin market segment will be the largest in future?

Answer: Lucintel forecasts that immunodeficiency diseases will remain the largest segment over the forecast period due to increasing focus towards the diagnosis and treatment based on individual patient and training of patients as most of the patients are not adaptable towards self administration.

Q7. In intravenous immunoglobulin market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region due to growing demand of therapies among clinicians, rising healthcare expenditure, and presence of major players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the intravenous immunoglobulin market by application (hypogammaglobulinemia, CIPD, immunodeficiency diseases, congenital aids, chronic lymphocytic leukemia, myasthenia gravis, multifocal motor neuropathy, kawasaki disease, guillain-barre syndrome, and others), distribution channel (intravenous and subcutaneous), end use (hospitals, homecare, specialty clinics, and others), form (liquid and lyophilized), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Intravenous Immunoglobulin Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Intravenous Immunoglobulin Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Intravenous Immunoglobulin Market by Application
    • 3.3.1: Hypogammaglobulinemia
    • 3.3.2: CIPD
    • 3.3.3: Immunodeficiency Diseases
    • 3.3.4: Congenital AIDS
    • 3.3.5: Chronic Lymphocytic Leukemia
    • 3.3.6: Myasthenia Gravis
    • 3.3.7: Multifocal Motor Neuropathy
    • 3.3.8: Kawasaki Disease
    • 3.3.9: Guillain-Barre Syndrome
  • 3.4: Global Intravenous Immunoglobulin Market by Distribution Channel
    • 3.4.1: Intravenous
    • 3.4.2: Subcutaneous
  • 3.5: Global Intravenous Immunoglobulin Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Homecare
    • 3.5.3: Specialty Clinics
    • 3.5.4: Others
  • 3.6: Global Intravenous Immunoglobulin Market by Form
    • 3.6.1: Liquid
    • 3.6.2: Lyophilized

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Intravenous Immunoglobulin Market by Region
  • 4.2: North American Intravenous Immunoglobulin Market
    • 4.2.2: North American Intravenous Immunoglobulin Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.3: European Intravenous Immunoglobulin Market
    • 4.3.1: European Intravenous Immunoglobulin Market by Application: Hypogammaglobulinemia, CIPD, Immunodeficiency Diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, Guillain-Barre Syndrome, and Others
    • 4.3.2: European Intravenous Immunoglobulin Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.4: APAC Intravenous Immunoglobulin Market
    • 4.4.1: APAC Intravenous Immunoglobulin Market by Application: Hypogammaglobulinemia, CIPD, Immunodeficiency Diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, Guillain-Barre Syndrome, and Others
    • 4.4.2: APAC Intravenous Immunoglobulin Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.5: ROW Intravenous Immunoglobulin Market
    • 4.5.1: ROW Intravenous Immunoglobulin Market by Application: Hypogammaglobulinemia, CIPD, Immunodeficiency Diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, Guillain-Barre Syndrome, and Others
    • 4.5.2: ROW Intravenous Immunoglobulin Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Intravenous Immunoglobulin Market by Application
    • 6.1.2: Growth Opportunities for the Global Intravenous Immunoglobulin Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Intravenous Immunoglobulin Market by End Use
    • 6.1.4: Growth Opportunities for the Global Intravenous Immunoglobulin Market by Form
    • 6.1.5: Growth Opportunities for the Global Intravenous Immunoglobulin Market by Region
  • 6.2: Emerging Trends in the Global Intravenous Immunoglobulin Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Intravenous Immunoglobulin Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Intravenous Immunoglobulin Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Baxter
  • 7.2: Bayer
  • 7.3: Merck
  • 7.4: Biotest
  • 7.5: Top Bio
  • 7.6: CSL
  • 7.7: Octapharma
  • 7.8: Grifols
  • 7.9: Kedrion
  • 7.10: Takeda Pharmaceuical